- Webinar scheduled for Thursday, November
17, 2022, at 11:00 a.m.
EST
- Featuring key opinion leader discussion on current treatment
landscape
NEW
YORK, Nov. 9, 2022 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com),
a clinical-stage pharmaceutical company focused on the development
of oral drug delivery platforms, today announced that it will host
a data presentation on newly released safety and efficacy data from
the Phase 2 trial of its oral insulin candidate (ORMD-0801) to
reduce liver fat content in Type 2 Diabetes ("T2D") patients with
non-alcoholic steatohepatitis ("NASH") on Thursday, November 17, 2022, at 11:00 a.m. Eastern Standard Time.
Professor Yaron Ilan,
M.D., Director of the Department of Medicine at the
Hebrew University-Hadassah Medical
Center, and Joel Neutel,
M.D., Director of Research, at the Orange County Research
Center and Memorial Research Medical Clinic, will provide
commentary on this data and the need for a NASH treatment that is
safe and well-tolerated.
The formal presentation will be followed by a live question and
answer session with Dr. Ilan and Dr. Neutel, who served as primary
investigators of this study.
To register for the event, please click the following link:
https://touchconference.zoom.us/webinar/register/WN_dy3jzksKQA6kBKZdT5a0_g
The live and archived webinar of this event may be accessed on
Oramed's website under Events and Presentations.
Professor Yaron Ilan,
M.D.
Dr. Yaron Ilan is the
Director of the Department of Medicine at the Hebrew University-Hadassah Medical Center. Dr. Ilan
served as the Vice Dean of the Hebrew
University-Hadassah Medical School. Dr. Ilan was a Visiting
Professor at Harvard University,
working on novel immunotherapies. His main area of research is
development of immunomodulatory drugs for fatty liver disease,
diabetes, inflammatory bowel disease and liver cancer. Dr. Ilan
holds over 50 patents for discoveries based on his innovative
research and has authored more than 300 articles. He is the
inventor of several drugs and medical devices developed by
pharmaceutical companies, several that have reached the clinical
market. Dr. Ilan is the founder of several companies and is a
medical director and advisor for biotech companies.
Joel Neutel, M.D.
Dr.
Neutel serves as Director of Research at the Orange County Research
Center in Orange County,
California and at the Memorial Research Medical Clinic in
Long Beach, California, where he
has served as Study Principal Investigator on several hundred
multinational cardiovascular & metabolic trials. Dr. Neutel has
had extensive experience serving the biopharmaceutical industry in
the areas of clinical and academic research, as well as marketing
strategic planning. After receiving his medical degree at the
University of Witwatersrand in Johannesburg, South Africa, Dr. Neutel
completed his internship and residency in internal medicine at the
Veterans Administration Medical Center in Long Beach and The University of California, Irvine. Dr. Neutel has
authored numerous abstracts, journal articles and book chapters. He
has conducted extensive research in such disciplines as
cardiovascular medicine, endocrinology, and central nervous system
disorders, with special attention to the pharmacotherapy of the
diseases in these areas.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals
(Nasdaq/TASE: ORMP) is a platform technology pioneer in the field
of oral delivery solutions for drugs currently delivered via
injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein
Oral Delivery (POD™) technology. Oramed is seeking to transform the
treatment of diabetes through its proprietary lead candidate,
ORMD-0801, which is being evaluated in two pivotal Phase 3 trials
and has the potential to be the first commercial oral insulin
capsule for the treatment of diabetes. In addition, Oramed is
developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule
(ORMD-0901).
For more information, please visit www.oramed.com
Forward-Looking Statements
This press release contains
forward-looking statements. For example, we are using
forward-looking statements when we discuss the potential of
ORMD-0801 to be the first commercial oral insulin capsule for the
treatment of diabetes. In addition, historic results of scientific
research and clinical trials do not guarantee that the conclusions
of future research or trials will suggest identical or even similar
conclusions. These forward-looking statements are based on the
current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including the risks and uncertainties
related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and finally that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed' s
reports filed from time to time with the Securities and Exchange
Commission.
Company Contact
Zach
Herschfus
+1-844-9-ORAMED
zach@oramed.com
View original
content:https://www.prnewswire.com/news-releases/oramed-to-host-webinar-highlighting-detailed-safety-and-efficacy-data-from-its-positive-phase-2-clinical-trial-of-ormd-0801-for-nash-301673007.html
SOURCE Oramed Pharmaceuticals Inc.